About Bridge-like lipid transfer protein family member 1
Bridge-like lipid transfer protein family member 1 (BLTP1) is a protein
from Homo sapiens identified by UniProt accession
Q2LD37, 5005 residues long.
MolForge cross-references it against 0 known binders and
157 disease associations.
Target properties
| Protein name | Bridge-like lipid transfer protein family member 1 |
|---|
| UniProt accession | Q2LD37 |
|---|
| Gene | BLTP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 5005 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (157)
Diseases linked to this target (Open Targets).
- Alkuraya-Kucinskas syndrome · score 0.76
- mean platelet volume · score 0.56
- platelet count · score 0.38
- arthrogryposis multiplex congenita · score 0.38
- renal agenesis · score 0.37
- Hemivertebrae · score 0.37
- right aortic arch · score 0.37
- Talipes equinovarus · score 0.36
- clubfoot · score 0.36
- fetal akinesia deformation sequence · score 0.33
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (5005 residues)
MDQRKNESIV PSITQLEDFL TEHNSNVVWL LVATILSCGW IIYLTYYNSR NVGLILTLVL NRLYKHGYIH IGSFSFSVLS GKVMVREIYY ITEDMSIRIQ DGFIIFRWWK MYNPKQKQHD PKAETRLYIT VNDFEFHVYN RSDLYGRLQE LFGLEPTIIP PKKDDDKTRE IGRTRTQSKI ERVKVKTESQ DPTSSWRSLI PVIKVNVSTG RLAFGNHYQP QTLCINFDDA FLTYTTKPPS SHLDQFMHIV KGKLENVRVM LVPSPRYVGL QNDEPPRLMG EGFVVMQSND VDIYYYMDEP GLVPEETEEN IEGEMSSEDC KLQDLPPCWG LDIVCGKGTD FNYGPWADRQ RDCLWKFFFP PDYQVLKVSE IAQPGRPRQI LAFELRMNII ADATIDLLFT KNRETNAVHV NVGAGSYLEI NIPMTVEENG YTPAIKGQLL HVDATTSMQY RTLLEAEMLA FHINASYPRI WNMPQTWQCE LEVYKATYHF IFAQKNFFTD LIQDWSSDSP PDIFSFVPYT WNFKIMFHQF EMIWAANQHN WIDCSTKQQE NVYLAACGET LNIDFSLPFT DFVPATCNTK FSLRGEDVDL HLFLPDCHPS KYSLFMLVKN CHPNKMIHDT GIPAECQSGQ KTVKPKWRNV TQEKSGWVEC WTVPSVMLTI DYTWHPIYPQ KADEQLKQSL SEMEETMLSV LRPSQKTSDR VVSSPSTSSR PPIDPSELPP DKLHVEMELS PDSQITLYGP LLNAFLCIKE NYFGEDDMYM DFEEVISSPV LSLSTSSSSG WTAVGMENDK KENEGSAKSI HPLALRPWDI TVLVNLYKVH GRLPVHGTTD GPECPTAFLE RLCFEMKKGF RETMLQLILS PLNVFVSDNY QQRPPVDEVL REGHINLSGL QLRAHAMFSA EGLPLGSDSL EYAWLIDVQA GSLTAKVTAP QLACLLEWGQ TFVFHVVCRE YELERPKSVI ICQHGIDRRF CESKLSCIPG PCPTSDDLKY TMIRLAVDGA DIYIVEHGCA TNIKMGAIRV ANCNLHNQSV GEGISAAIQD FQVRQYIEQL NNCRIGLQPA VLRRAYWLEA GSANLGLITV DIALAADHHS KHEAQRHFLE THDARTKRLW FLWPDDILKN KRCRNKCGCL GGCRFFGGTV TGLDFFKLEE LTPSSSSAFS STSAESDMYY GQSLLQPGEW IITKEIPKII DGNVNGMKRK EWENKSVGIE VERKTQHLSL QVPLRSHSSS SSSEENSSSS AAQPLLAGEK ESPSSVADDH LVQKEFLHGT KRDDGQASIP TEISGNSPVS PNTQDKSVGQ SPLRSPLKRQ ASVCSTRLGS TKSLTAAFYG DKQPVTVGVQ FSSDVSRSDE NVLDSPKQRR SFGSFPYTPS ADSNSFHQYR SMDSSMSMAD SEAYFSAAEE FEPISSDEGP GTYPGRKKKK KQTQQIDYSR GSIYHSVEGP LTGHGESIQD SRTLPFKTHP SQASFVSALG GEDDVIEHLY IVEGEKTVES EQITPQQPVM NCYQTYLTQF QVINWSVKHP TNKRTSKSSL HRPLDLDTPT SEESSSSFEQ LSVPTFKVIK QGLTANSLLD RGMQLSGSTS NTPYTPLEKK LADNTDDETL TEEWTLDQPV SQTRTTAIVE VKGTVDIVLT PLVAEALDRY IEAMVHCAST RHPAAIVDDL HAKVLREAVQ NSKTTFSENL SSKQDIRGTK TEQSTIGTTN QGQAQTNLTM KQDNVTIKGL QTNVSIPKVN LCLLQASVEE SPTTAPSRSV THVSLVALCF DRIATQVRMN RGVVEETSNN AEPGRTSNFD RYVHATKMQP QSSGSLRSNA GAEKGKEIAA KLNIHRVHGQ LRGLDTTDIG TCAITAIPFE KSKVLFTLEE LDEFTFVDET DQQAVPDVTR IGPSQEKWGW IMFECGLENL TIKGGRQSGA VLYNSFGIMG KASDTERGGV LTSNNSSDSP TGSGYNTDVS DDNLPCDRTS PSSDLNGNSV SDEQDEGVES DDLKKDLPLM PPPPDSCSMK LTIKEIWFSF AAPTNVRSHT HAFSRQLNLL STATPAVGAW LVPIDQLKSS LNKLETEGTL RICAVMGCIM TEALENKSVH FPLRSKYNRL TKVARFLQEN PSCLLCNILH HYLHQANYSI IDDATMSDGL PALVTLKKGL VALARQWMKF IVVTPAFKGV SLHRPAQPLK PQIAMDHEHE DGLGLDNGGG LQSDTSADGA EFEFDAATVS EHTMLLEGTA NRPPPGSSGP VTGAEIMRKL SKTHTHSDSA LKIKGIHPYH SLSYTSGDTA TDSPVHVGRA GMPVKDSPRK ESLLSYLTGS FPSLHNLLEG TPQRSSAAVK SSSLTRTGNT VATDMLSEHP LLSEPSSVSF YNWMSNAVGN RGSVLQESPV TKSGHNSLPT GVAPNLPTIP SASDFNTVLS SDQNTLDGTH SQHSTSQDDV AGVEEANQGF PAVQLADAQV VFKPLLSHTG IQSQDTMPFC YRMYFGEHLS FSGTLDCLRA DIVDSDTAKE RKGKRARRQG HVNLPPLEFK PALMLGTFSI SAVVMEKSVC TPQNSTSALS FHDLSKRYYN TFHCNFTISC QSISQHVDMA LVRLIHQFST MIDDIKATQT DIKLSRYTAG SASPTPTFKT RKHRDFRSSD FSRSSRGSLN GGNRVNNAKN KRTNNENNKK ESRNKNSLGR SERRTSKVSR KGSKDVVDHM TIHMDDSDSI TVSEQSEPSA ECWQNMYKLL NFYSLISDPT GILEKSSETF GPAGVRSPTE PTCKVVFENE QDNSSLTKTQ RKRSLVTSEP QHVTLIVFGI GMVNRTHLEA DIGGLTMESE LKRIHGSFTL KEKMKDVLHQ KMTETCATAH IGGVNIVLLE GITPNIQLED FPTSPTSTAK QEFLTVVKCS IAKSQALYSA QRGLKTNNAA VFKVGAISIN IPQHPATLHS MMVRSSHQLS KQISDLIRQP STAPQPVKED IATPLPSEKT PTSVNQTPVE TNEFPQLPEG LEKKPIVLKF SAMLDGIAIG AALLPSLKAE YKMGRMRSHG MTGAQTRFTF ELPNHRLRFT SKVSATDMST IPPSASLNLP PVTMSGKYIM EEHDSYSDQV WSIDELPSKQ GYYLQGNYLR CVAEVGSFEH NLTTDLLNHL VFVQKVFMKE VNEVIQKVSG GEQPIPLWNE HDGTADGDKP KILLYSLNLQ FKGIQVTATT PSMRAVRFET GLIELELSNR LQTKASPGSS SYLKLFGKCQ VDLNLALGQI VKHQVYEEAG SDFHQVAYFK TRIGLRNALR EEISGSSDRE AVLITLNRPI VYAQPVAFDR AVLFWLNYKA AYDNWNEQRM ALHKDIHMAT KEVVDMLPGI QQTSAQAFGT LFLQLTVNDL GICLPITNTA QSNHTGDLDT GSALVLTIES TLITACSSES LVSKGHFKNF CIRFADGFET SWDDWKPEIH GDLVMNACVV PDGTYEVCSR TTGQAAAESS SAGTWTLNVL WKMCGIDVHM DPNIGKRLNA LGNTLTTLTG EEDIDDIADL NSVNIADLSD EDEVDTMSPT IHTEATDYRR QAASASQPGE LRGRKIMKRI VDIRELNEQA KVIDDLKKLG ASEGTINQEI QRYQQLESVA VNDIRRDVRK KLRRSSMRAA SLKDKWGLSY KPSYSRSKSI SASGRPPLKR MERASSRVGE TEELPEIRVD AASPGPRVTF NIQDTFPEET ELDLLSVTIE GPSHYSSNSE GSCSVFSSPK TPGGFSPGIP FQTEEGRRDD SLSSTSEDSE KDEKDEDHER ERFYIYRKPS HTSRKKATGF AAVHQLFTER WPTTPVNRSL SGTATERNID FELDIRVEID SGKCVLHPTT LLQEHDDISL RRSYDRSSRS LDQDSPSKKK KFQTNYASTT HLMTGKKVPS SLQTKPSDLE TTVFYIPGVD VKLHYNSKTL KTESPNASRG SSLPRTLSKE SKLYGMKDSA TSPPSPPLPS TVQSKTNTLL PPQPPPIPAA KGKGSGGVKT AKLYAWVALQ SLPEEMVISP CLLDFLEKAL ETIPITPVER NYTAVSSQDE DMGHFEIPDP MEESTTSLVS SSTSAYSSFP VDVVVYVRVQ PSQIKFSCLP VSRVECMLKL PSLDLVFSSN RGELETLGTT YPAETLSPGG NATQSGTKTS ASKTGIPGSS GLGSPLGRSR HSSSQSDLTS SSSSSSGLSF TACMSDFSLY VFHPYGAGKQ KTAVSGLTPG SGGLGNVDEE PTSVTGRKDS LSINLEFVKV SLSRIRRSGG ASFFESQSVS KSASKMDTTL INISAVCDIG SASFKYDMRR LSEILAFPRA WYRRSIARRL FLGDQTINLP TSGPGTPDSI EGVSQHLSPE SSRKAYCKTW EQPSQSASFT HMPQSPNVFN EHMTNSTMSP GTVGQSLKSP ASIRSRSVSD SSVPRRDSLS KTSTPFNKSN KAASQQGTPW ETLVVFAINL KQLNVQMNMS NVMGNTTWTT SGLKSQGRLS VGSNRDREIS MSVGLGRSQL DSKGGVVGGT IDVNALEMVA HISEHPNQQP SHKIQITMGS TEARVDYMGS SILMGIFSNA DLKLQDEWKV NLYNTLDSSI TDKSEIFVHG DLKWDIFQVM ISRSTTPDLI KIGMKLQEFF TQQFDTSKRA LSTWGPVPYL PPKTMTSNLE KSSQEQLLDA AHHRHWPGVL KVVSGCHISL FQIPLPEDGM QFGGSMSLHG NHMTLACFHG PNFRSKSWAL FHLEEPNIAF WTEAQKIWED GSSDHSTYIV QTLDFHLGHN TMVTKPCGAL ESPMATITKI TRRRHENPPH GVASVKEWFN YVTATRNEEL NLLRNVDANN TENSTTVKNS SLLSGFRGGS SYNHETETIF ALPRMQLDFK SIHVQEPQEP SLQDASLKPK VECSVVTEFT DHICVTMDAE LIMFLHDLVS AYLKEKEKAI FPPRILSTRP GQKSPIIIHD DNSSDKDRED SITYTTVDWR DFMCNTWHLE PTLRLISWTG RKIDPVGVDY ILQKLGFHHA RTTIPKWLQR GVMDPLDKVL SVLIKKLGTA LQDEKEKKGK DKEEH
Explore Bridge-like lipid transfer protein family member 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets